Federal Marijuana Legalization Unlikely in 2026 Despite Rescheduling Push

Rescheduling Timeline Extends Past 2026

The DEA's administrative rescheduling process won't conclude in 2026. Following the Department of Health and Human Services recommendation in August 2023 to move cannabis to Schedule III, the DEA published a Notice of Proposed Rulemaking in May 2024. The agency is currently reviewing more than 43,000 public comments submitted during the 60-day comment period that closed in July 2024.

Administrative law requires the DEA to address substantive comments in a final rule. Industry attorneys tracking the docket estimate final publication in Federal Register between March and June 2027—then comes a 60-day implementation window, followed by near-certain legal challenges from multiple stakeholder groups.

Congressional Legalization Bills Remain Dormant

No federal legalization bill has advanced to floor consideration in the 119th Congress. The Cannabis Administration and Opportunity Act, reintroduced in the Senate in February 2026, remains in the Finance Committee. Its House companion, the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act 2.0), hasn't received a markup hearing in the Judiciary Committee.

Senate Majority Leader dynamics make floor action before the 2026 midterms mathematically improbable. No legalization provision has been attached to any must-pass vehicle—defense authorization, appropriations, continuing resolutions. Congressional leadership hasn't scheduled legalization for a vote in either chamber.

What Rescheduling Would and Wouldn't Change

Rescheduling to Schedule III would eliminate Section 280E tax penalties but wouldn't legalize cannabis under federal law. Schedule III substances remain controlled. Interstate commerce, import/export, and unlicensed possession remain federal crimes. The change would allow state-licensed operators to deduct ordinary business expenses—a shift worth an estimated $1.8 billion annually to the multistate operator sector.

Banking access, FDA oversight gaps, and state-federal licensing conflicts would persist under Schedule III—rescheduling is a tax fix, not a legalization framework.

The Controlled Substances Act would still classify cannabis as a federally regulated drug. SAFE Banking Act provisions, which passed the House six times between 2019 and 2023, remain the only near-term path to depository access for cannabis operators. Rescheduling doesn't touch that problem.

What to Watch in 2027

The DEA final rule and potential legal challenges will define the 2027 landscape. If the agency publishes a final Schedule III rule by mid-2027, implementation would begin 60 days later. That puts the earliest effective date in Q3 2027. Litigation from prohibitionist groups challenging the rule, or from reform advocates arguing the rule doesn't go far enough, could delay implementation further.

For full background on this story, see the CannIntel topic hub on Federal Marijuana Legalization 2026. The next major signal: DEA publication of a final rule in the Federal Register, expected no earlier than March 2027.